Table 2. Association of Medical Therapy With Postdischarge 30-Day Neurologic Events After Propensity Score Matching^a.

Outcome	Dual Antiplatelet Therapyb				Oral Anticoagulantc				Dual Antiplatelet Therapy vs Oral Anticoagulantd
	HR (95% CI)	Absolute Risk, %		P Value	HR (95% CI)	Absolute Risk, %		P Value	HR (95% CI)	Absolute Risk, %		P Value
		Yes	No			Yes	No			Dual Antiplatelet Therapy	Oral Anticoagulant
Femoral Cohort
No.	31 192				22 022				24 668
30-d stroke	1.04 (0.74-1.46)	0.55	0.52	.81	1.03 (0.73-1.46)	0.57	0.55	.87	1.09 (0.79-1.52)	0.55	0.51	.59
30-d TIA	0.87 (0.51-1.49)	0.18	0.21	.61	0.84 (0.46-1.52)	0.19	0.24	.56	0.83 (0.49-1.40)	0.21	0.25	.48
30-d stroke or TIA	0.99 (0.74-1.33)	0.73	0.73	.96	0.98 (0.73-1.33)	0.76	0.77	.92	0.99 (0.75-1.30)	0.74	0.76	.92
Nonfemoral Cohort
No.	6338				4608				5550
30-d stroke	1.02 (0.54-1.95)	0.71	0.69	.94	0.93 (0.47-1.83)	0.75	0.82	.83	0.84 (0.44-1.64)	0.63	0.75	.62
30-d TIA	0.61 (0.22-1.72)	0.17	0.28	.35	1.31 (0.29-5.84)	0.18	0.15	.72	0.62 (0.20-1.90)	0.19	0.32	.40
30-d stroke or TIA	0.87 (0.49-1.57)	0.84	0.97	.65	0.98 (0.52-1.87)	0.94	0.97	.96	0.74 (0.41-1.34)	0.78	1.06	.33

Abbreviations: HR, hazard ratio; TIA, transient ischemic attack.

^aCharacteristics of patients in the propensity-matched analyses are provided in eTables 7 through 12 in the Supplement. All medications for the propensity-matched analyses were based on discharge medications.

^bPatients taking single-antiplatelet therapy were eligible to be included in the no dual antiplatelet therapy group. Patients taking oral anticoagulants were eligible for either group.

^cPatients taking any antiplatelet regimen were eligible for either group.

^dOnly patients taking dual antiplatelet therapy without oral anticoagulants were eligible for the dual antiplatelet therapy group and patients taking oral anticoagulants with single antiplatelet therapy but no dual antiplatelet therapy were eligible for the oral anticoagulant group.